Trials want to determine the efficacy of ivermectin – Lexington-Fayette, Kentucky

Lexington-Fayette, Kentucky 2021-10-07 12:42:24 –

The warnings from the Food and Drug Administration and the Centers for Disease Control and Prevention are clear. Ivermectin, a drug commonly used to treat parasitic infections, should not be used as a treatment for COVID-19 outside of clinical practice.

However, there are legal and safe ways to access ivermectin as a possible treatment for the virus.

Dr. Rowena Dolor is one of the researchers in a government-funded trial investigating several reused drugs, including ivermectin, for their potential efficacy against COVID-19.

“We did some laboratory research showing that it has some antiviral effect on SARS-CoV-2 and other viruses, but we don’t know if that laboratory effect will be converted to humans,” Doller said. Stated. “So we want to do some research to scientifically test whether ivermectin benefits patients with COVID.”

The study also tests steroid inhalers commonly used to treat asthma and COPD, as well as antidepressants for their effectiveness against COVID-19.

However, ivermectin is an experimental treatment that has recently gained attention due to its large purchases from agricultural stores. The doses of these products are for treating large animals such as horses and cows, and the FDA reported that many people who took the drug appeared in hospitals with serious side effects.

In human clinical trials, safety is a top priority while using ivermectin.

“In this study, we’re actually taking the medication based on the patient’s weight, and at the lowest dose based on the desired drug concentration needed to treat the infection,” said Dolor.

The ACTIV-6 study, which includes ivermectin, is looking for adults who test positive for COVID-19 and are experiencing symptoms. With hundreds of patients already enrolled in about 40 clinical settings, researchers want to expand their research to include thousands of patients in 250 clinical settings.

Researchers add that it is important to obtain a diverse pool of participants, especially from the black and Hispanic communities.

“We want to know that the results of these studies can be applied to colored patients or the colored community,” Droa said. “But fortunately, so far at least 25% of site participants have been black or Hispanic American.”

click here Find out more about the COVID-19 clinical treatment trial.

Source link

Back to top button